AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025

Core Insights - Amgen announced that the Phase 3 VESALIUS-CV clinical trial of Repatha met its dual primary endpoints, demonstrating significant reduction in major adverse cardiovascular events (MACE) in high-risk patients without prior heart attack or stroke [2][3] - The results will be presented at the American Heart Association Scientific Sessions in November 2025, highlighting Repatha's position as a leading LDL-C lowering therapy [1][2] Group 1: Clinical Trial Results - The VESALIUS-CV trial is the first to show that Repatha significantly reduces the risk of MACE in individuals without a history of heart attack or stroke [2] - The trial's findings emphasize the importance of early intervention and maintaining low LDL-C levels to prevent cardiovascular events [2][3] Group 2: Real-World Evidence - Data from the VESALIUS-REAL global observational study, covering over 1.1 million patients across 11 countries, will provide insights into lipid management and MACE incidence in high-risk populations [3] - The REPATHA-CE trial, the largest real-world study of patients with established atherosclerotic cardiovascular disease (ASCVD), demonstrates Repatha's effectiveness in reducing MACE in clinical practice [4] Group 3: Company Commitment - Amgen is committed to advancing cardiovascular care through innovative treatments and extensive research, as evidenced by its ongoing clinical trials and real-world studies [2][7] - The company aims to address multiple interrelated risk factors associated with cardiovascular disease, reflecting a comprehensive approach to prevention and care [7]